TruthArchive.ai - Related Video Feed

Some batches of the vaccine may have serious side effects or be degraded. The batch number can be checked to see what to expect. Documentation shows that certain batches have more serious adverse effects. Even the best batches from Pfizer and Moderna had a high rate of serious adverse events in the short term, around 1800.

A recent study involving 99 million COVID vaccine recipients found increased risks of neurological and heart disorders, described as rare but significant. For example, the risk of brain swelling increased by 378%, myocarditis by 610%, and Guillain Barre syndrome by 286%. The cumulative risk of these adverse events raises questions about the overall safety of vaccines, especially considering the CDC's childhood vaccination schedule, which includes 72 doses without long-term safety trials. Each vaccine has a list of potential side effects, many serious, yet they are often labeled as rare. Historical data shows a rise in chronic illnesses among vaccinated children, suggesting a troubling trend. The notion that vaccine injuries are non-existent is misleading, as many children are experiencing adverse effects. It’s crucial to recognize and evaluate these risks comprehensively.

Myocarditis is a rare side effect of the vaccine, with only 1% of cases resulting in death. However, it is important to note that myocarditis has a high mortality rate of 50% within five years and many deaths within ten years. This poses significant risks for individuals who develop myocarditis after vaccination. The question remains whether the vaccine is necessary for an epidemic that some argue is no more severe than the flu.

We are witnessing a significant increase in cases of myocarditis, with thousands reported in recent studies compared to only a few cases in the past. The potential long-term effects of vaccine-induced myocarditis are concerning, with some cases leading to cardiac arrests years after vaccination. This suggests that the current cases may just be the beginning, and regulatory concerns should extend for at least 5 to 15 years post-vaccination.

The largest COVID study found a link between the vaccine and heart/brain disorders. Data from 100 million people in 8 countries showed slight increases in conditions like myocarditis and Guillain Barre syndrome. The study does not prove the vaccine caused these issues. Despite concerns, experts say the vaccine's benefits outweigh the risks. People like Elizabeth Foster question the vaccine's impact on their health. It's important to consult with a doctor before deciding to get vaccinated.

The discussion centers on evidence linking myocarditis and pericarditis to mRNA vaccination and the proposed mechanism behind it. It references a 2022 German study reporting that endomyocardial biopsy data from people with myocarditis showed cardiac detection of the spike protein and CD4+ T cell–dominated inflammation, suggesting a vaccine-triggered autoimmune reaction. The presenters note headlines at the time comparing myocarditis risk to infection, with claims that infection causes more myocarditis, and remind that vaccines were said not to stop transmission. They then cite a large Israeli population study from the same year involving subjects not vaccinated against SARS-CoV-2, which found no increase in the incidence of myocarditis or pericarditis, implying no observed vaccine-related signal in that cohort. Attention shifts to a more recent study published in Circulation by the American Heart Association, described as a high-impact, non-fringe journal, indicating a clearer mechanism has been demonstrated. The study described used an experimental mouse model to induce cardiac damage and then compared it to human cases with heart damage following vaccination. It states that T cells from patients with acute myocarditis or myopericarditis recognize vaccine-encoded spike epitopes that are homologous to cardiac self proteins, meaning the immune response to the spike protein can cross-react with heart tissues. The researchers further report that functional responses to potassium channels in patients with mild pericarditis after mRNA vaccination, but not in patients with COVID-19, showed an expanded pattern of cytokine production similar to that observed in myopericarditis mice and in autoimmune myocarditis. In plain terms, the summary of their takeaway is that post-mRNA vaccine myopericarditis is driven by molecular mimicry: the immune system cannot distinguish self from non-self, leading to an autoimmune attack on heart tissue in susceptible patients. The distribution of the vaccine (its widespread dissemination) is cited as a factor that makes patients susceptible by promoting heart-homing imprinting, effectively creating an anti-heart autoimmune response. The speakers emphasize that this Circulation article is a top-tier source, underscoring that the mechanism has been demonstrated with both animal models and human pathology, supporting the claim that the phenomenon has a defined immunological basis.

The symposium covers the potential safety and threat of “replicating” vaccines, especially LepriCon (leprecon) vaccines, in the context of Covid-19 vaccines and genome‑editing concepts. The speakers present a chain of claims and concerns, some drawing on reports and others presenting theories about how these next‑generation vaccines could behave in humans and populations. Key points and claims presented - Emerging mechanisms and risks: The panel notes that blood vessel inflammation and thrombosis mechanisms are increasingly observed, including in vaccine contexts, with examples from individuals who needed limb amputation and others who developed severe vascular events after vaccination. One case involved a 70‑year‑old man who, after a third dose, developed embolic events necessitating shoulder joint surgery, and another where a 60‑year‑old man developed acute limb ischemia and died; both are presented as suggesting a serious vascular mechanism linked to vaccination, though causal connections are not established. - Replicating/vector vaccines and their concerns:荒川博士 and others discuss LepiCon vaccines as vaccines that replicate inside the body. The concept involves “replicating viral vectors” where the genome can mutate and evolve during replication. The green‑highlighted segment in a slide (the antigen gene) plus a blue/orange segment (replicating gene cassette) is used to describe how LepriCon vaccines are designed to carry viral genes and replicate, with the assertion that replication, mutation, and recombination can occur, potentially generating new variants inside the host. - Differences from conventional vaccines: The discussion contrasts LepriCon vaccines with standard mRNA vaccines. In conventional mRNA vaccines, messenger RNA is delivered and translated into antigen proteins, then degraded; in LepriCon vaccines, replicating RNA/DNA can persist and continue producing antigen, with mutation and recombination possible. The panel emphasizes that LepriCon vaccines use replicating/copying mechanisms and that the genetic material can be copied in ways that differ from natural human biology, potentially creating unpredictable variants. - Central dogma and exceptions: The speakers reference the central dogma (DNA → RNA → protein) but note exceptions in viruses, including RNA viruses that can reverse‑transcribe to DNA (retroviruses) and RNA viruses that replicate RNA directly. They discuss how LepriCon vaccines would rely on replicative processes that do not follow the usual linear flow and why this could complicate predictions about safety and behavior in humans. - Potential for unintended spread and environmental impact: A major concern raised is that self‑replicating vectors could spread beyond the vaccinated individual, via exosomes or other intercellular transport, creating secondary infections or non‑target spread. Exosomes could ferry replicating genetic material, raising fears of new infection chains or “outbreaks” stemming from the vaccine itself, and even suggesting the possibility of vaccination‑induced spread akin to an attenuated or modified pathogen. - Safety signals and immunology concerns: The discussion touches on immune system risks, including immune dysregulation, autoimmune phenomena, and unexpected inflammatory responses. IGG4‑related disease is highlighted as a potential adverse outcome post‑vaccination, with descriptions of glandular and systemic involvement and the idea that high IGG4 levels could have immunosuppressive effects that alter responses to infection or vaccination. The panel notes observed increases in certain immunoglobulin subclasses after multiple LepriCon doses and discusses the possibility of immune tolerance or enhanced immune responses that could be harmful. - Historical and theoretical context: References are made to past epidemics and speculative pandemics caused by misused or dangerous vaccine platforms, drawing on central molecular biology concepts and historical anecdotes about how vaccines can be designed and misused. The discussion frames LepriCon vaccines as a high‑risk platform that could, in theory, generate recombinants, escape mutations, or cause unintended immune and inflammatory consequences. - Clinical and regulatory implications: The speakers call for caution, arguing that more evidence is needed before approving or widespread use of LepriCon vaccines. They emphasize the need for long‑term observation and transparent communication about risks, and criticize the potential for insufficient understanding among healthcare workers and the public. They also urge that any future vaccine development should consider the possibility of genome editing, recombination, and exosome‑mediated spread, and stress the importance of not underestimating possible adverse effects. - Real‑world observations and skepticism about hype: Several speakers underscore that the danger is not merely hypothetical; there are reports of adverse events, including stroke‑like conditions, inflammatory diseases, and immune dysregulation in vaccinated individuals. They stress that the evolution and mutation of replicating vaccines could outpace current surveillance methods, and that “information manipulation” or lack of transparent reporting could mislead the public about risks. - Final reflections and call to action: The concluding messages advocate recognizing the potential failures of messenger RNA vaccines and acknowledging that both conventional and replicating platforms may carry risks. The speakers urge ongoing critical analysis, cautious progression, and robust verification of claims through transparent, independent investigation. They close with thanks to the organizers and a hope that the discussion may contribute to broader public awareness and informed decision‑making. Notable emphasis and unique considerations - The core concern centers on LepriCon vaccines’ replication, mutation, and potential to spread beyond the vaccinated person; exosome transport and genomic/cellular integration are highlighted as mechanisms that could generate new risks not present with non‑replicating vaccines. - The discussion stresses that IGG4 responses could become alarmingly high after certain doses, potentially leading to immunosuppressive effects or autoimmune phenomena, and presents IGG4‑related disease as a potential complication to monitor. - The speakers insist that safety and transparency are paramount, and that misinformation or optimistic narratives about rapid vaccine development could lead to harm if new platforms are adopted without comprehensive evaluation. Overall, the symposium foregrounds cautious scrutiny of replicating vaccine platforms, frames potential biological and regulatory risks, and calls for careful, evidence‑based assessment before broader deployment.

The speaker discusses a significant increase in myocarditis cases post-vaccination, with studies showing abnormal cardiac scans in vaccinated individuals. They suggest a potential link between mRNA vaccines and heart inflammation, emphasizing the need for long-term monitoring. Research indicates that mRNA and spike proteins can cause myocarditis, posing a concern for all mRNA products. The heart appears to be a vulnerable target due to various factors.

Speaker 0 states that the study confirms suspicions from the past five years that common sense has deteriorated in the population. The study analyzed the VAERS system from the 1990s to 2024 and examined PRRs (proportional reporting ratios), which measure how many more adverse events occur with the COVID shots compared to the flu shot or other vaccines. It reports 8686 safety signals of neuropsychiatric adverse events, with some up to 3,000 times higher than the flu shot. The safety signal threshold defined by CDC/FDA for PRRs is greater than two, and all reported signals exceeded this threshold. The listed conditions include schizophrenia, dementia, Alzheimer's, cognitive impairment, strokes, brain clots, homicidal tendencies, homicidal behavior, and psychosis, described as people hallucinating and brain damage. The speaker notes that this large number of safety signals aligns with a recent study indicating that people who had strokes showed toxic spike protein production in their brains for up to seventeen months after vaccination, which the speaker suggests explains the observed deterioration in cognitive function.

Based on initial reports, 1 in 1300 individuals experienced Bell's palsy after vaccination. Other reported side effects include disturbances in menstrual cycles (1 in 906), shingles (1 in 450), tinnitus (1 in 160), and heart palpitations (1 in 143). These numbers may increase as more data is collected. The CDC values this data as it provides a more accurate safety profile. With 10 million vaccinated individuals, real percentages of side effects can be determined.

The speaker observed vasculitis, or inflammation of the blood vessels, in the brain tissue of almost all cases examined post-vaccination. Lymphocytes aggregate around small vessels, indicating inflammation possibly triggered by an antigenic structure like spike protein. This was described as one of the most alarming findings. Individuals with this complication may experience transient defects like loss of speech, unconsciousness, or blindness, but the brain can compensate if there is no major inflammation or hemorrhage. The speaker clarified that the individuals did not die from the vasculitis itself. It's possible for vaccinated individuals to experience these symptoms without knowing the underlying cause. Changes in character have been reported in some vaccinated individuals, which may be related to this inflammation.

They discuss the number of people who have experienced long-term health issues after receiving the vaccine. The speaker asks if it's hundreds or thousands, and Helen responds that it's actually around 10. She mentions a report from April 2023, which states that there were 11,289 medically significant or serious reports. Out of those, 1,062 were listed as disabled, 118 were considered life-threatening, and 184 resulted in death. Helen clarifies that the long-term consequences are not in the hundreds or thousands, but rather around 10.

The speaker discusses a paper from Denmark that reveals a significant variation in suspected adverse reactions to the Pfizer vaccine. The data shows a 1,000-fold difference in incidence depending on the batch of vaccines administered. This information is currently gaining popularity.

The speaker discusses the recognition of side effects from the Covid-19 vaccine by public authorities. After two years of conspiracy theories, the link between the vaccine and various health issues is now acknowledged. Only 72 out of 241 cases have received compensation for vaccine-related adverse effects. The main incidents recognized are cardiac disorders, particularly myocarditis and pericarditis. Neurological disorders, such as facial paralysis, and severe vascular issues like strokes, thrombosis, and pulmonary embolisms, have also been reported. The difficulty in reporting adverse events and the low number of victims seeking compensation are highlighted. The speaker suggests that the media downplayed the severity of these effects during vaccination campaigns.

Four studies are cited as showing significant lot variability in the vaccine batches. The speaker notes that the variability is substantial across lots, with some batches from the early 2021 period appearing to be the most dangerous. They state that some lots are linked to large numbers of adverse events, while other lots are linked to no adverse events at all, describing these as “duds.” According to the speaker, these problematic batches may result from several issues: the mRNA being degraded, or the cold-chain failure such as being left out of the refrigerator for too long, or problems in the manufacturing process that rendered the batch ineffective. The implication is that these dud batches were not manufactured properly. The speaker emphasizes that some of these batches had devastating effects on individuals. They further claim that these batches were probably contaminated with high levels of DNA plasmids from the manufacturing process, extremely high levels of mRNA, and even heavy metal contamination. The range of issues is described as broad, indicating multiple types of contamination or quality problems in different batches. The overall assertion is that not a single batch appears to be the same as another; there is clear heterogeneity across batches, with some batches causing major adverse events and others causing none.

The speaker describes a severe post-vaccination experience, saying the vaccine “took my immune system and just shook it around again,” and noting that “that’s still going on.” They reference reading evidence about adverse reactions, including “damage to the immune system,” and acknowledge they were not made aware of these risks beforehand. They recount losing the use of their hands for about three weeks and realizing they were “in real trouble.” The speaker was invited by Robin Monarchy to discuss the experience, and by that time they realized they “weren’t the only one that was suffering.” They contrast this personal ordeal with a sense of media over-saturation, saying they have “stopped watching TV.” They share a cartoon memory of a guy interviewing two Quakers who ask, “How come none of your community has got COVID?” and the Quakers respond, “Well, we don’t watch TV,” remarking, “It’s so true, man,” and noting that “so much of the sickness is in our heads now.” They describe feeling trapped between trusting what “your heart tells you is right” and what appears to be the prevailing narrative, and they emphasize the difficulty of communicating their feelings to family. The speaker mentions taking a risk by speaking out, noting they were “pleased to see that it went around without too much of flack,” but they did experience some backlash, particularly from people they least wanted to upset. A central concern expressed is fear about what vaccination could do to their children, describing it as perhaps “the biggest part of the reason” for speaking out and talking to their daughters about the possibility that they “may not be able to have kids.” They acknowledge that at that point in life, their daughters “don’t probably care,” implying a tension between present concerns and future implications. The speaker concludes with that vaccination remains a source of personal risk and disclosure within their family discussions.

Speaker 0 asks Speaker 1 to explain why the vaccine causes myocarditis and pericarditis. Speaker 1 mentions rare reports of myocarditis and pericarditis associated with vaccination but does not provide a clear explanation. Speaker 0 insists on understanding the mechanism and questions why the vaccine is considered safe without addressing the risks. Speaker 2 intervenes, suggesting that Speaker 1 will address the question later. Speaker 1 talks about the benefit-risk ratio and the global recommendation of health authorities. Speaker 0 reiterates the question, to which Speaker 1 agrees to provide a response later. Speaker 2 confirms this agreement.

Before COVID-19, I only encountered two cases of myocarditis in my entire career as a cardiologist. However, now I see two cases per day in the clinic. We have learned that COVID-19 can cause myocarditis, and various organizations conducted screening programs in 2020. These programs found a few cases that met the definition of myocarditis, but none were serious or resulted in hospitalizations or deaths. After the introduction of vaccines, regulatory agencies acknowledged that the vaccines can cause COVID-19 vaccine-induced myocarditis, which can be fatal. It's important for people to understand that there is a risk associated with every vaccine shot they take.

The panel discusses replication (replicon) vaccines and their potential dangers, focusing on how they differ from conventional messenger RNA (mRNA) vaccines and what new risks might emerge as this technology develops. Key points and concerns raised - Replicon vaccines concept and fundamental differences - Replicon vaccines use replication-capable genetic material, so the embedded genetic information not only makes antigen proteins but also multiplies inside the cell. They are described as having both constitutive function (the ability to make proteins) and, crucially, the capacity to replicate, which distinguishes them from traditional, non-replicating mRNA vaccines. - It is explained that replication introduces additional mutation and recombination opportunities, because the RNA genome is copied more than once, and the process can produce variants that differ from the original design. - Central dogma exceptions and viral biology - The speakers explain that while the central dogma (DNA → RNA → protein) generally governs biology, some viruses violate this, with RNA viruses that replicate via RNA-dependent replication and even some reverse-transcribing retroviruses that convert RNA to DNA and integrate into genomes. This context is used to frame why replicon vaccines could behave unpredictably. - Potential risks of replication and spread - A core concern is that the replicon approach might allow the vaccine genome to spread beyond the initial target cells, potentially reaching other cells and tissues, or even spreading to other people via exosomes or other means. Exosomes can transport DNA, RNA, and proteins between cells; thus, the replicon genome could in theory be disseminated. - The possibility of homologous or heterologous recombination between replicon genomes and wild-type viruses could yield new variants. The panel emphasizes the difficulty of controlling such recombination in a living system. - Specific material and design considerations - The use of viral components like spike protein genes in replicon vaccines raises concerns about how these proteins might mutate or recombine during replication, potentially altering antigen presentation or safety. - A concern is raised about the lack of repair mechanisms in RNA replication (as opposed to DNA replication), which could make error rates higher and lead to unpredictable changes. - The panel notes that current replicon vaccine designs (including those using alphavirus backbones) inherently carry high mutation and recombination risk, and that the replicating systems may encounter unpredictable evolutionary dynamics inside the human body. - Safety signals and clinical anecdotes - The speakers cite cases of adverse events temporally associated with vaccines, including vascular inflammation and thrombosis, stroke-like events, and myocarditis, to illustrate that immune responses to vaccines can be complex and occasionally severe. They emphasize that such observations do not establish causality, but argue they warrant careful scrutiny. - There are references to cases of acute vascular and neural complications following repeated vaccination, and to broader immune dysregulation phenomena, including IGG4-related disease and immune dysregulation syndromes that can involve multiple organs. - One example concerns a patient who developed sudden limb problems after the third dose, requiring surgery; another describes myocardial involvement after multiple doses and subsequent inflammatory sequelae. - DNA contamination and analytical findings - Kevin McKernan’s analysis of certain Japanese CoronaVac vaccines is cited: both DNA contamination and the presence of SV40 promoter elements were detected in some vaccine lots, with DNA amounts exceeding some regulatory benchmarks in at least one case. The concern is that DNA contamination, or the presence of promoter sequences, could influence integration or expression in unintended ways. - It is noted that vaccines using lipid nanoparticles can potentially deliver nucleic acids into cells; in the presence of exons or promoter sequences, there could be unintended cellular uptake and expression. - Implications for public health and policy - The panel underscores the need for caution, thorough investigation, and long-term observation of any replication-based vaccine platform before broad deployment. There is a call to evaluate risks, monitor long-term outcomes, and consider the possibility that replication-competent constructs could drive unforeseen evolutionary dynamics within hosts or communities. - There is contention about how information is communicated to the public, with particular emphasis on avoiding misinformation while ensuring that scientific uncertainties are transparently discussed. - Broader scientific context and forward-looking stance - The speakers discuss how the field’s approach to gene-based vaccines is evolving rapidly, and they stress that the compatibility of replicon systems with human biology is not yet fully understood. - They frame their discussion as not merely about current vaccines but about the trajectory of vaccine platforms: if replication-based or self-dispersing systems prove too risky or unpredictable, the prudent path might be to favor conventional, non-replicating strategies until safety, efficacy, and containment of unintended spread are more firmly established. Closing and takeaways - The session closes with emphasis on careful evaluation of replicon vaccines, awareness that viral genetics can behave differently in humans than in theory, and a call for continued discussion, independent verification, and transparent communication as the technology develops. - Throughout, speakers acknowledge the complexity of immune responses to vaccines, the potential for unexpected adverse events, and the importance of safeguarding public health while advancing vaccine science.

The speaker asks Pfizer and Moderna to explain how the COVID-19 vaccine causes myocarditis. The response from the doctors is that the exact mechanism is still being studied, but myocarditis is generally an autoimmune response that can occur after COVID-19 or other infections. The speaker questions if other organs could also be affected by the vaccine, but the doctors explain that ongoing surveillance is in place to monitor potential risks. The speaker expresses concern about the lack of initial disclosure of these risks. The doctors emphasize the importance of preventing COVID-19 and state that the reported rate of myocarditis is around 2-3 per 100,000 doses. The speaker argues that if it can happen to the heart, it could happen to other organs. The conversation ends due to time constraints.

The speaker discusses the increasing awareness and concern surrounding myocarditis as a result of COVID-19 vaccines. They mention that there are now 800 peer-reviewed papers on COVID vaccine-induced myocarditis, with a rate of heart damage at 2.5% in two studies. They explain the pathogenesis of vaccine-induced cardiac arrest and highlight the fatality of this condition. The speaker also mentions cases of athletes and public figures who have experienced myocarditis after vaccination. They express concern about the lingering effects of myocarditis and the recurrence of symptoms. The speaker concludes by discussing the case of a European athlete who experienced a cardiac arrest two years after vaccination, emphasizing the ongoing risk associated with myocarditis.

We are vaccinating millions, and while there are reports of deaths following vaccinations, there is no evidence that the vaccine causes these deaths. Adverse reactions must be reported, but many go unreported, potentially skewing data. For instance, only 5% of adverse reactions may reach the monitoring database. There have been serious cases, including hospitalizations, that are not being documented properly. Despite the numbers, experts assert that the vaccine is safe and effective. It's crucial for the public to understand that while adverse events will occur, they are often coincidental. The vaccine remains vital for public health, and getting vaccinated is strongly encouraged.

They classified post-vaccine issues into three categories: immediate effects like pain, swelling, and redness, but vomiting, diarrhea, fainting, etc. are not considered immediate side effects. They also mentioned Covid-like illnesses that resemble Covid-19, with data from Israel showing that 11% of people had Covid within two weeks of the anti-Covid injection. They warned about post-Covid injection syndrome (P0IS or P0V), which includes various inflammatory, multisystemic problems like cardiac, neurological, hematological, vascular, immune system, reproductive health, cancer, and congenital complications. This classification highlights the wide range of adverse effects and raises concerns about the vaccine's safety.

Speaker 0 asks Speaker 1 to explain the process of how the vaccine causes myocarditis and pericarditis. Speaker 1 mentions rare reports of myocarditis and pericarditis associated with vaccination. Speaker 0 insists on an explanation of the mechanism, but Speaker 1 does not provide a direct answer. Speaker 1 emphasizes that all medicines have benefits and side effects and refers to the benefit-risk ratio. Speaker 0 continues to press for an explanation of the biochemical pathway, but Speaker 1 agrees to provide a response later. The transcript ends with Speaker 2 confirming Speaker 1's agreement to give a further response.

COVID nineteen mRNA injections actually destroy eight point four percent of nonrenewable eye cells in just seventy five days. This was of sixty four healthy young adults who did receive Pfizer's mRNA injection, and they did find irreversible structural damage to the eye's corneal endothelium. The study found that endothelial cell density decreased by 8.4%. Cell size variation increased by 7.7%, which does indicate cell stress. Hexagonality, which means normal shaped cells, actually decreased by about 2% indicating structural distortions, and central corneal thickness increased by 2.8% indicating swelling and fluid imbalance. We have to remember that injury to this base layer of nonrenewable cells can lead to blurred vision, chronic swelling, and even blindness in severe cases. The harms of these shots just keep piling up.